The 35-year veteran of Bristol-Myers Squibb brings manufacturing operations and product launch leadership expertise to drive NTx commercialization efforts.
Bioinformatics and biomanufacturing company NTx has announced the addition of biopharma industry veteran Nancy Rurkowski to the company’s Board of Directors. NTx focuses on the advancement of medical products and material sciences through cell-free, innovative biomanufacturing solutions.
NTx is currently commercializing biomanufacturing systems NTxpress®, NTxscribe® and bioinformatics platform, DruID, for discovery of natural products.
NTx biosynthesis technology is built for mRNA and proteins that are made in-vitro. Its biomanufacturing processes can easily be scaled to meet fluctuating supply needs allowing companies to increase and streamline their production as they respond to changing global demands.
Rurkowski brings with her over 3.5 decades of experience in pharmaceutical and biologics operations from Bristol-Myers Squibb. She has held global leadership roles across strategic sourcing, new product launch, global supply chain, process development, quality, and manufacturing operations throughout her storied 35 year career at BMS.
Most recently, Rurkowski worked in executive roles in pharmaceuticals, working closely with research and development and commercial teams of Bristol-Myers Squibb to launch new products. Rurkowski led a biologics manufacturing site for clinical and commercial supply of drug substances along with being responsible for worldwide quality of the biologics drug substance manufacturing network.
Nancy Rurkowski was excited to share her experience with NTx. “NTx has developed a number of technology platforms that have enabled step changes in the discovery, development and manufacture of vaccines and biologics.” She continued, “Over the course of my career, I have served as a bridge between scientists and plant engineers to realize the potential of technology and I am excited to share this experience to help NTx drive market adoption.”
The current NTx Board of Directors is composed of distinguished pharmaceutical and biotechnology leaders that include former U.S. Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense Andrew Weber; former director of the Los Alamos National Laboratory Charles McMillan; Managing Principal at Camino Real Capital PartnersManaging Principal at Camino Real Capital Partners Thomas Nickoloff; NTx co-founder, CEO and CSO, Dr. Alex Koglin, Chief Operations Officer at NTx Joseph Sullivan; Managing Partner at Anzu Partners David Seldin; and NTx co-founder and CTO, Dr. Michael Humbert.
NTX co-founder, CEO and CSO Dr. Alex Koglin was thrilled about the appointment stating, “Her expertise across manufacturing, supply chain, technical operations and more, will be invaluable as we move into our new facility and ramp capacity.”
